Treatment of buffy coat platelets in platelet additive solution with the mirasol pathogen reduction technology system

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 1, 2013, Pages 44-48

  Castrillo, Azucena ^a   Cardoso, Marcia ^b   Rouse, Lindsay ^b  

^a Transfusion Centre of Galicia Centro de Transfusión de Galicia   (Spain)

^b Terumo BCT Inc   (United States)

Author keywords

Buffy coat platelets; Mirasol; PAS IIIM; Pathogen reduction technology

Indexed keywords

BUFFY COAT PLATELET CONCENTRATE; LACTATE DEHYDROGENASE; LACTIC ACID; MISCELLANEOUS DRUGS AND AGENTS; PADGEM PROTEIN; PLATELET ADDITIVE SOLUTION; RANTES; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CELL METABOLISM; CONTROLLED STUDY; GLUCOSE INTAKE; LACTATE DEHYDROGENASE BLOOD LEVEL; PATHOGEN REDUCTION SYSTEM; PH; PROTEIN EXPRESSION; THROMBOCYTE PRESERVATION;

EID: 84874370531     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000345679     Document Type: Article

References (25)

1. Parada C, Villalba J, Alvarez M, Puig N, Planelles D, Ramada C, Montoro J, Roig R: Trypanosoma rangeli in a blood donor at the Valencian Blood Transfusion Centre. Vox Sang 2010;99:193-194.
2. Mackenzie JS, Gubler DJ, Petersen LR: Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004;10:S98-S109.
3. Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, de VH, Desenclos JC: Estimated risk of chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008;48:1333-1341.
4. Dodd RY: XMRV, Q fever and other emerging infections: impact on management of blood safety. ISBT Sci Ser 2011;6:119-123.
5. AuBuchon JP, Prowse CV (eds): Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda, AABB Press, 2010.
6. Solheim BG: Pathogen reduction of blood components. Transfus Apher Sci 2008;39:75-82.
7. Marschner S, Goodrich R: Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
8. Centro de Transfusion de Galicia: Annual Report 2010. http://ctg.sergas.es/
9. Ross D, Holme S, Hartman P, Reece K, Oubilla L, Heaton A: A quick visual method for quality control of platelet concentrates. Transfusion 1986;26:550.
10. Guide to the Preparation, Use and Quality Assurance of Blood Components. Strasbourg, Council of Europe, 2011.
11. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns A: Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006;90:279-285.
12. Picker SM, Oustianskaia L, Schneider V, Gathof BS: Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009;97:26-33.
13. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-1341.
14. Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, Johansson PI: In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010;50:2210-2219.
15. Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T: The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010;8: 186-192.
16. Ostrowski SR, Bochsen L, Windelov NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, Johansson PI: Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011;51:344-356.
17. Michelson AD, Barnard MR, Hechtman HB, Mac-Gregor H, Connolly RJ, Loscalzo J, Valeri CR: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-11882.
18. Kluter H, Bubel S, Kirchner H, Wilhelm D: Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999;39:1179-1184.
19. Mirasol Clinical Evaluation Study Group: A Randomized controlled clinical trial evaluating the performance and safety of platelets treated with Mirasol pathogen reduction technology. Transfusion 2010;50:2362-2375.
20. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA: Proceedings of a consensus conference: pathogen inactivationmaking decisions about new technologies. Transfus Med Rev 2008;22:1-34.
21. Custer B, Agapova M, Martinez RH: The costeffectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-2473.
22. Marschner S, Fast LD, Baldwin WM III, Slichter SJ, Goodrich RP: White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010;50:2489-2498.
23. Mintz PD: Cesium cessation? An advantage of pathogen reduction treatments. Transfusion 2011; 51:1369-1376.
24. Fast LD, DiLeone G, Marschner S: Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51:1397-1404.
25. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM: Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007;84:1174-1182.